[go: up one dir, main page]

PE20030978A1 - Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)-amino]-metil}-fenoxi)-acetico - Google Patents

Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)-amino]-metil}-fenoxi)-acetico

Info

Publication number
PE20030978A1
PE20030978A1 PE2003000086A PE2003000086A PE20030978A1 PE 20030978 A1 PE20030978 A1 PE 20030978A1 PE 2003000086 A PE2003000086 A PE 2003000086A PE 2003000086 A PE2003000086 A PE 2003000086A PE 20030978 A1 PE20030978 A1 PE 20030978A1
Authority
PE
Peru
Prior art keywords
pyridin
amino
phenoxy
methyl
terc
Prior art date
Application number
PE2003000086A
Other languages
English (en)
Inventor
Kimberly O'keefe Cameron
Chandra Aggarwal Prakash
Bruce Allen Lefker
Kim Anne Johnson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030978A1 publication Critical patent/PE20030978A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS COMO ACIDO 2-(4-{[(3-CARBOXIMETOXIBENCIL)-(PIRIDIN-3-SULFONIL)-AMINO]-METIL} FENIL)-2-METILPROPIONICO, ACIDO (3-{[(4-(2-HIDROXI-1,1-DIMETILETIL)BENCIL)-(PIRIDIN-3-SULFONIL)AMINO]METIL} FENOXI)ACETICO, ACIDO (3-{[(4-TERC-BUTILBENCIL)-(PIRIDIN-N-OXIDO-3-SULFONIL)-AMINO]-METIL} FENOXI)-ACETICO. ACIDO (5-{[(4-TERC-BUTILBENCIL)-(PIRIDIN-3-SULFONIL)-AMINO]-METIL} HIDROXIFENOXI)ACETICO. SE REFIERE TAMBIEN AL COMPUESTO ACIDO 2-{4-[PIRIDIN-N-OXIDO-3-SULFONILAMINO)METIL]FENIL}-2-METIL-PROPIONICO, GLUCORONICO DEL ACIDO (3-{[(4-(2-HIDROXI-1,1-DIMETILETIL)BENCIL)-(PIRIDIN-3-SULFONIL)AMINO]METIL} FENOXI)ACETICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE OSTEOPOROSIS
PE2003000086A 2002-01-31 2003-01-28 Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)-amino]-metil}-fenoxi)-acetico PE20030978A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35374802P 2002-01-31 2002-01-31

Publications (1)

Publication Number Publication Date
PE20030978A1 true PE20030978A1 (es) 2003-11-19

Family

ID=27663249

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000086A PE20030978A1 (es) 2002-01-31 2003-01-28 Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)-amino]-metil}-fenoxi)-acetico

Country Status (29)

Country Link
US (1) US6852863B2 (es)
EP (1) EP1470109A1 (es)
JP (1) JP2005521668A (es)
KR (1) KR20040077884A (es)
CN (1) CN1625549A (es)
AP (1) AP2004003094A0 (es)
AR (1) AR038332A1 (es)
BR (1) BR0307339A (es)
CA (1) CA2473984A1 (es)
EA (1) EA200400724A1 (es)
EC (1) ECSP045215A (es)
GB (1) GB2400100B (es)
HN (1) HN2003000051A (es)
HR (1) HRP20040683A2 (es)
HU (1) HUP0500012A2 (es)
IL (1) IL162167A0 (es)
IS (1) IS7281A (es)
MA (1) MA27169A1 (es)
MX (1) MXPA04004960A (es)
NO (1) NO20043569D0 (es)
OA (1) OA12760A (es)
PA (1) PA8564601A1 (es)
PE (1) PE20030978A1 (es)
PL (1) PL371982A1 (es)
TN (1) TNSN04138A1 (es)
TW (1) TW200302080A (es)
UY (1) UY27632A1 (es)
WO (1) WO2003064391A1 (es)
ZA (1) ZA200404067B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
TWI332937B (en) * 2005-04-20 2010-11-11 Lg Chemical Ltd Additive for non-aqueous electrolyte and secondary battery using the same
MX2009001062A (es) * 2006-07-28 2009-02-06 Pfizer Prod Inc Agonistas de ep2.
WO2008112164A2 (en) 2007-03-08 2008-09-18 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
JP5136640B2 (ja) * 2008-03-12 2013-02-06 宇部興産株式会社 ピリジルアミノ酢酸化合物
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
JP2012502048A (ja) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
CN102448940B (zh) 2009-03-30 2015-10-21 宇部兴产株式会社 用于青光眼的治疗或预防的医药组合物
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)

Also Published As

Publication number Publication date
EP1470109A1 (en) 2004-10-27
OA12760A (en) 2006-07-04
ECSP045215A (es) 2004-09-28
NO20043569L (no) 2004-08-26
HRP20040683A2 (en) 2004-10-31
EA200400724A1 (ru) 2004-12-30
GB2400100A (en) 2004-10-06
ZA200404067B (en) 2005-08-29
AR038332A1 (es) 2005-01-12
GB0413967D0 (en) 2004-07-28
TW200302080A (en) 2003-08-01
MXPA04004960A (es) 2005-04-08
CA2473984A1 (en) 2003-08-07
JP2005521668A (ja) 2005-07-21
HUP0500012A2 (hu) 2005-04-28
PL371982A1 (en) 2005-07-11
NO20043569D0 (no) 2004-08-26
HN2003000051A (es) 2003-09-24
BR0307339A (pt) 2004-12-07
GB2400100B (en) 2006-04-12
IS7281A (is) 2004-05-21
US6852863B2 (en) 2005-02-08
TNSN04138A1 (fr) 2007-03-12
IL162167A0 (en) 2005-11-20
UY27632A1 (es) 2003-08-29
KR20040077884A (ko) 2004-09-07
WO2003064391A1 (en) 2003-08-07
AP2004003094A0 (en) 2004-09-30
PA8564601A1 (es) 2003-09-05
CN1625549A (zh) 2005-06-08
MA27169A1 (fr) 2005-01-03
US20030216445A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
PE20030978A1 (es) Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)-amino]-metil}-fenoxi)-acetico
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
PE20081120A1 (es) Derivados de hidantoina como inhibidores de metaloproteinasas de matriz (mmp)
TW200716610A (en) Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
PE20040516A1 (es) Derivados de 1,2-azol
TW200716107A (en) Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
NZ601786A (en) Novel compounds and compositions and methods of use
EP2529624A3 (en) Substituted benzene fungicides
MX338024B (es) Derivado de dibencilamina opticamente activa y metodo para prepararla.
MX2010001415A (es) Procedimiento para sintetizar compuestos utiles para tratar hepatitis c.
NO20080942L (no) Amino-5-[4-(difluormetoksy)-fenyl]-5-fenylimidazolonforbindelser som inhibitorer av beta-sekretase (BACE)
PE20091002A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion
PE20060825A1 (es) Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
UA92354C2 (en) Amino acid salts of rosiglitazone
PE20121732A1 (es) Derivados de ciclohexano espiro-condensado como inhibidores de hsl utiles en el tratamiento de la diabetes
WO2009041705A3 (en) 5-membered heterocyclic compounds as proton pump inhibitors
EA200801507A1 (ru) Оптически активные карбаматы, способ их получения и их применение в качестве фармацевтических промежуточных соединений
NZ600017A (en) 5-hydroxypyrimidine-4-carboxamide derivative
EA200701260A1 (ru) Циннаматные соли бета-2 адренергического агониста
PE20070640A1 (es) Compuestos derivados de pirazol-isoquinolina urea como inhibidores de la cinasa p38
NO20060379L (no) Den polymorfe form av 4-[6-acetyl-3-[3-(4-acetyl-3-hydroksy-2-propylfenyltio)propoksy]-2-propylfenoksybutansyre
NO20074303L (no) 7-{4-[2-(2,6-diklor-4-metylfenoksy)etoksy]fenyl}-3,9-diazabisyklo-[3.3.1]non-6-en-6-karboksylsyresyklopropyl-(2,3-dimetylbenzyl)amid som renininhibitor til behandling av hypertensjon
PE20090243A1 (es) Compuestos de imidazol sustituido como inhibidores de renina
PE20210859A1 (es) Inhibidores de triazol glicolato oxidasa
UY32336A (es) Nuevos compuestos de acido 2-({ [(1Z)-1-2(2-amino-1,3-tiazol-4-il)-2-{ [(3S)-1-({ [5-hidroxi-4-oxo-1,4-dihidropiridin-2-il)-5-oxo-4-propil-4, 5 - dihidro - 1H - 1, 2, 4 - trialzol - 1 - il]sulfonil} carbamoil) -2 - oxazetidin -3 -il] amino} - 2 - oxoetiliden] amino} oxi) - 2 - metilpropanoico, composiciones farmacéuticas conteniendolos y aplicaciones.

Legal Events

Date Code Title Description
FD Application declared void or lapsed